Study: Affluent people more likely to undergo bowel cancer screening than deprived counterparts

NewsGuard 100/100 Score

Affluent people are 50 per cent more likely to take part in bowel cancer screening than their deprived counterparts, according to a study published in the British Journal of Cancer (BJC).

The Cancer Research UK study, which looked at how many people in the London area returned their home testing kits for bowel cancer, found that only one in three people in the most deprived areas participated.

This compared with one in two people in the wealthiest areas.

The figures are part of the National Awareness and Early Diagnosis Initiative (NAEDI) supplement published in the BJC, which for the first time brings together research underpinning the initiative.

Professor Jane Wardle, lead author from Cancer Research UK's Health Behaviour Research Centre based at University College London, said: "There's a real danger that bowel cancer could increasingly become a disease of lower social class if these figures hold true across the UK.

"We know that more than 90 per cent of bowel cancer patients survive if the disease is caught at the earliest stage, compared with around six per cent for cases detected at the latest stage.

"Screening helps to spot early signs of bowel cancer, as well as pre-cancerous growths that don't cause any symptoms, so it's important that everyone who receives a testing kit takes part."

Bowel screening kits - faecal occult blood (FOB) tests - are sent through the post every two years to people aged between 60 and 74 years old2. People take their own stool samples at home and then send the kit back for testing. The results are posted out within two weeks.

Professor Wardle continued: "Our study reveals a worrying pattern, but we don't know why social class has played such a major role in screening uptake.

"Bowel cancer screening may not be pleasant, but this seems to be less of a deterrent for those who are better off.

"Future research will need to discover what the key barriers are."

The study monitored the response to the roll out of bowel cancer screening across London in the first 30 months of the programme.

Over 400,000 test kits were sent out. The researchers categorised the addresses to which kits were sent into five groups, based on the neighbourhood characteristics of that postcode area, from the most affluent to the most deprived.

Sara Hiom, director of health information at Cancer Research UK, said: "Some people may be put off by the idea of bowel cancer screening, but it can save lives.

"Cancer Research UK, the NHS and the Department of Health are key players in the National Awareness and Early Diagnosis Initiative (NAEDI), which aims to cut cancer deaths through early diagnosis of the disease. Reducing inequalities in uptake of screening is a crucial part of this."

Professor Mike Richards, National Cancer Director at the Department of Health, said: "It is now generally accepted that late diagnosis of cancer is a key reason for England having lower cancer survival rates than other comparable countries. This supplement is very important in helping to tackle this problem, as it sets out what is known about the causes of late diagnosis and what can be done to tackle those causes. Through the national screening programmes and NAEDI, the Department of Health, the NHS and key partners such as Cancer Research UK are working to achieve earlier detection and to save lives."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
First UK real-world study shows promise for sacituzumab govitecan in metastatic breast cancer